Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Wednesday, 11 September 2013
- AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer AstraZeneca and Merck & Co Inc , known outside the United States and Canada as MSD, today announced a worldwide licensing agreement.
- Monday, 26 August 2013
- MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune
- Wednesday, 31 July 2013
- AstraZeneca and FibroGen collaborate to develop and commercialise FG-4592, a treatment for anaemia in chronic kidney disease and end-stage renal disease Collaboration to include US, China and selected other markets